Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathies

Diabetes and Metabolism

Volumn 36, Issue 1, 2010, Pages 1-10

  Daroux, M ^a,b   Prevost G ^a,b   Maillard Lefebvre, H ^a,b   Gaxatte, C ^a,b   D'Agati, V D ^c   Schmidt, A M ^c   Boulanger, É ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Columbia University ^*  (United States)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Fibrosis; Glomerulosclerosis; RAGE; Review

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; HEMOGLOBIN A1C; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; MATRILYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULAR CELL ADHESION MOLECULE 1;

AGING; CELL TYPE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIET; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; INTERSTITIUM; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; RENOVASCULAR DISEASE; REVIEW;

AGING; ANIMALS; BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE; MESANGIAL CELLS; PODOCYTES; RECEPTORS, IMMUNOLOGIC;

EID: 76649145110     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.06.005     Document Type: Review

References (120)

1. Dikow R., and Ritz E. In: Davidson A.M., Stewart Cameron J., Grünfeld J.P., Ponticelli C., Ritz E., Winearls C.G., et al. (Eds). The patient with diabetes mellitus (2006), International textbook of clinical nephrology 661-673
2. Miyata T. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end-products in renal failure. Nippon Jinzo Gakkai Shi 38 (1996) 191-197
3. Simonson M.S. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 71 (2007) 846-854
4. Bohlender J.M., Franke S., Stein G., and Wolf G. Advanced glycation end-products and the kidney. Am J Physiol Renal Physiol 289 (2005) 645-659
5. Hartog J.W., Smit A.J., van Son W.J., Navis G., Gans R.O., Wolffenbuttel B.H., et al. Advanced glycation end-products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 43 (2004) 966-975
6. Berrou J., Tostivint I., Verrecchia F., Berthier C., Boulanger E., Mauviel A., et al. Advanced glycation end-products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 23 (2009) 513-520
7. Boulanger E., Puisieux F., Gaxatte C., and Wautier J.L. Aging: role and control of glycation. Rev Med Interne 28 (2007) 832-840
8. Maillard L. Action des acides aminés sur les sucres ; formation des mélanoïdes par voie méthodique. C R Acad Sci (1912) 66-68
9. Ohgami N., Nagai R., Ikemoto M., Arai H., Miyazaki A., Hakamata H., et al. CD36, serves as a receptor for advanced glycation end-products (AGE). J Diabetes Complications 16 (2002) 56-59
10. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end-products (AGE): a new member of the AGE-receptor complex. Mol Med 1 (1995) 634-646
11. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., et al. Isolation and characterization of two binding proteins for advanced glycosylation end-products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267 (1992) 14987-14997
12. Stern D., Yan S.D., Yan S.F., and Schmidt A.M. Receptor for advanced glycation end-products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54 (2002) 1615-1625
13. Wautier J.L., and Guillausseau P.J. Advanced glycation end-products, their receptors and diabetic angiopathy. Diabetes Metab 27 (2001) 535-542
14. Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end-products. PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23 (1994) 408-419
15. Kalea A.Z., Schmidt A.M., and Hudson B.I. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci 116 (2009) 621-637
16. Pettersson-Fernholm K., Forsblom C., Hudson B.I., Perola M., Grant P.J., and Groop P.H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52 (2003) 891-894
17. Prevost G., Fajardy I., Besmond C., Balkau B., Tichet J., Fontaine P., et al. Polymorphisms of the receptor of advanced glycation end-products (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab 31 (2005) 35-39
18. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 22 (2008) 1572-1580
19. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., et al. A soluble form of the receptor for advanced glycation end-products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22 (2008) 3716-3727
20. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end-products in tissues. Am J Pathol 143 (1993) 1699-1712
21. Soulis T., Thallas V., Youssef S., Gilbert R.E., McWilliam B.G., Murray-McIntosh R.P., et al. Advanced glycation end-products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40 (1997) 619-628
22. Boulanger E., Wautier M.P., Wautier J.L., Boval B., Panis Y., Wernert N., et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61 (2002) 148-156
23. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., et al. Expression of advanced glycation end-products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11 (2000) 1656-1666
24. Suzuki D., Toyoda M., Yamamoto N., Miyauchi M., Katoh M., Kimura M., et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 45 (2006) 435-441
25. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., and Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280 (2001) 685-694
26. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
27. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95 (2004) 233-238
28. Boulanger E., Grossin N., Wautier M.P., Taamma R., Wautier J.L., and Mesothelial. RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 71 (2007) 126-133
29. Lo C.S., Relf I.R., Myers K.A., and Wahlqvist M.L. Doppler ultrasound recognition of preclinical changes in arterial wall in diabetic subjects: compliance and pulse-wave damping. Diabetes Care 9 (1986) 27-31
30. Stitt A.W., Bucala R., and Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann N Y Acad Sci 811 (1997) 115-127
31. Yamada K., Miyahara Y., Hamaguchi K., Nakayama M., Nakano H., Nozaki O., et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 42 (1994) 354-361
32. Gugliucci A., and Bendayan M. Reaction of advanced glycation end-products with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 43 (1995) 591-600
33. Horie K., Miyata T., Maeda K., Miyata S., Sugiyama S., Sakai H., et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100 (1997) 2995-3004
34. Wautier M.P., Boulanger E., Guillausseau P.J., Massin P., and Wautier J.L. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb Haemost 91 (2004) 879-885
35. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., et al. Advanced glycation end-products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
36. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., et al. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96 (1995) 1395-1403
37. Giardino I., Edelstein D., and Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94 (1994) 110-117
38. Xu B., Ji Y., Yao K., Cao Y.X., and Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci 109 (2005) 439-446
39. Bucala R., Tracey K.J., and Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87 (1991) 432-438
40. Esposito C., Gerlach H., Brett J., Stern D., and Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170 (1989) 1387-1407
41. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end-products blocks hyperpermeability in diabetic rats. J Clin Invest 97 (1996) 238-243
42. Bulckaen H., Prevost G., Boulanger E., Robitaille G., Roquet V., Gaxatte C., et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Am J Physiol Heart Circ Physiol 294 (2008) 1562-1570
43. Brizzi M.F., Dentelli P., Rosso A., Calvi C., Gambino R., Cassader M., et al. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J 18 (2004) 1249-1251
44. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., et al. Advanced glycation end-product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277 (2002) 20309-20315
45. Ha H., and Lee H.B. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 77 Suppl. (2000) S19-25
46. Li Y.M., Mitsuhashi T., Wojciechowicz D., Shimizu N., Li J., Stitt A., et al. Molecular identity and cellular distribution of advanced glycation end-product receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 93 (1996) 11047-11052
47. He C.J., Zheng F., Stitt A., Striker L., Hattori M., and Vlassara H. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int 58 (2000) 1931-1940
48. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14 (2003) 1383-1395
49. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162 (2003) 1123-1137
50. Chuang P.Y., Yu Q., Fang W., Uribarri J., and He J.C. Advanced glycation end-products induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int 72 (2007) 965-976
51. Doublier S., Salvidio G., Lupia E., Ruotsalainen V., Verzola D., Deferrari G., et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52 (2003) 1023-1030
52. Lachapelle M., and Bendayan M. Contractile proteins in podocytes: immunocytochemical localization of actin and alpha-actinin in normal and nephrotic rat kidneys. Virchows Arch B Cell Pathol Incl Mol Pathol 60 (1991) 105-111
53. Ha T.S. High glucose and advanced glycosylated end-products affect the expression of alpha-actinin-4 in glomerular epithelial cells. Nephrology 11 (2006) 435-441
54. Kimura M., Toyoda M., Kato M., Kobayashi K., Abe M., Kobayashi T., et al. Expression of alpha-actinin-4 in human diabetic nephropathy. Intern Med 47 (2008) 1099-1106
55. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., et al. Advanced glycation end-products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 164 (2004) 1389-1397
56. Oldfield M.D., Bach L.A., Forbes J.M., Nikolic-Paterson D., McRobert A., Thallas V., et al. Advanced glycation end-products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end-products (RAGE). J Clin Invest 108 (2001) 1853-1863
57. Reiser K., McCormick R.J., and Rucker R.B. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J 6 (1992) 2439-2449
58. McLennan S.V., Fisher E.J., Yue D.K., and Turtle J.R. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 43 (1994) 1041-1045
59. Mott J.D., Khalifah R.G., Nagase H., Shield III C.F., Hudson J.K., and Hudson B.G. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52 (1997) 1302-1312
60. McLennan S.V., Martell S.K., and Yue D.K. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 51 (2002) 2612-2618
61. McLennan S.V., Kelly D.J., Schache M., Waltham M., Dy V., Langham R.G., et al. Advanced glycation end-products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?. Kidney Int 72 (2007) 481-488
62. Krishnamurti U., Rondeau E., Sraer J.D., Michael A.F., and Tsilibary E.C. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 272 (1997) 27966-27970
63. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., and Steffes M. Advanced glycation end-products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91 (1994) 11704-11708
64. Muller-Krebs S., Kihm L.P., Zeier B., Gross M.L., Deppisch R., Wieslander A., et al. Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 38 (2008) 296-305
65. Miyata T., Ueda Y., Yamada Y., Izuhara Y., Wada T., Jadoul M., et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end-product: carbonyl stress in uremia. J Am Soc Nephrol 9 (1998) 2349-2356
66. Foerster A., and Henle T. Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. Biochem Soc Trans 31 (2003) 1383-1385
67. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., He C., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end-products in renal failure patients. J Am Soc Nephrol 14 (2003) 728-731
68. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., Baliga S., et al. Dietary glycotoxins correlate with circulating advanced glycation end-product levels in renal failure patients. Am J Kidney Dis 42 (2003) 532-538
69. Gugliucci A., and Bendayan M. Renal fate of circulating advanced glycated end-products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39 (1996) 149-160
70. Kostolanska J., Jakus V., and Barak L. Monitoring of early and advanced glycation in relation to the occurrence of microvascular complications in children and adolescents with type 1 diabetes mellitus. Physiol Res 58 (2009) 553-561
71. Guo J., Ananthakrishnan R., Qu W., Lu Y., Reiniger N., Zeng S., et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 19 (2008) 961-972
72. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Birkeland K.I., et al. High serum levels of advanced glycation end-products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 25 (2005) 815-820
73. Suzuki D., Miyata T., Saotome N., Horie K., Inagi R., Yasuda Y., et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10 (1999) 822-832
74. de Leeuw K., Graaff R., de Vries R., Dullaart R.P., Smit A.J., Kallenberg C.G., et al. Accumulation of advanced glycation end-products in patients with systemic lupus erythematosus. Rheumatology 46 (2007) 1551-1556
75. Qing X., Pitashny M., Thomas D.B., Barrat F.J., Hogarth M.P., and Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 121 (2008) 61-73
76. Linden E., Cai W., He J.C., Xue C., Li Z., Winston J., et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end-products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 3 (2008) 691-698
77. Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12 (2003) 25-29
78. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., et al. Advanced glycation end-products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 91 (1994) 4766-4770
79. Glenn J.V., Beattie J.R., Barrett L., Frizzell N., Thorpe S.R., Boulton M.E., et al. Confocal Raman microscopy can quantify advanced glycation end-product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J 21 (2007) 3542-3552
80. Semba R.D., Ferrucci L., Fink J.C., Sun K., Beck J., Dalal M., et al. Advanced glycation end-products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53 (2009) 51-58
81. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., and Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 4 (2002) 191-209
82. Wong A., Luth H.J., Deuther-Conrad W., Dukic-Stefanovic S., Gasic-Milenkovic J., Arendt T., et al. Advanced glycation end-products co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 920 (2001) 32-40
83. Artwohl M., Graier W.F., Roden M., Bischof M., Freudenthaler A., Waldhausl W., et al. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52 (2003) 1240-1247
84. Luth H.J., Ogunlade V., Kuhla B., Kientsch-Engel R., Stahl P., Webster J., et al. Age- and stage-dependent accumulation of advanced glycation end-products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex 15 (2005) 211-220
85. Munch G., Luth H.J., Wong A., Arendt T., Hirsch E., Ravid R., et al. Crosslinking of alpha-synuclein by advanced glycation end-products: an early pathophysiological step in Lewy body formation?. J Chem Neuroanat 20 (2000) 253-257
86. Ma W., Lee S.E., Guo J., Qu W., Hudson B.I., Schmidt A.M., et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci 48 (2007) 1355-1361
87. Cai W., He J.C., Zhu L., Chen X., Zheng F., Striker G.E., et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173 (2008) 327-336
88. Teillet L., Verbeke P., Gouraud S., Bakala H., Borot-Laloi C., Heudes D., et al. Food restriction prevents advanced glycation end-product accumulation and retards kidney aging in lean rats. J Am Soc Nephrol 11 (2000) 1488-1497
89. Soulis T., Cooper M.E., Vranes D., Bucala R., and Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50 (1996) 627-634
90. Kelly D.J., Gilbert R.E., Cox A.J., Soulis T., Jerums G., and Cooper M.E. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12 (2001) 2098-2107
91. Peyroux J., and Sternberg M. Advanced glycation end-products (AGEs): pharmacological inhibition in diabetes. Pathol Biol 54 (2006) 405-419
92. Huijberts M.S., Wolffenbuttel B.H., Boudier H.A., Crijns F.R., Kruseman A.C., Poitevin P., et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92 (1993) 1407-1411
93. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 (1997) 895-899
94. Tsuchida K., Makita Z., Yamagishi S., Atsumi T., Miyoshi H., Obara S., et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end-product inhibitor, OPB-9195. Diabetologia 42 (1999) 579-588
95. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., Huijberts M.S., Poitevin P., Swennen G.N., et al. Breakers of advanced glycation end-products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 95 (1998) 4630-4634
96. Booth A.A., Khalifah R.G., Todd P., and Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end-products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272 (1997) 5430-5437
97. Degenhardt T.P., Alderson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61 (2002) 939-950
98. Williams M.E. New therapies for advanced glycation end-product nephrotoxicity: current challenges. Am J Kidney Dis 41 (2003) S42-S47
99. Voziyan P.A., and Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62 (2005) 1671-1681
100. Berrone E., Beltramo E., Solimine C., Ape A.U., and Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281 (2006) 9307-9313
101. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 (2003) 294-299
102. Stirban A., Negrean M., Stratmann B., Gawlowski T., Horstmann T., Gotting C., et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end-products in individuals with type 2 diabetes. Diabetes Care 29 (2006) 2064-2071
103. Coughlan M.T., Forbes J.M., and Cooper M.E. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int 106 Suppl. (2007) S54-60
104. Peppa M., Brem H., Cai W., Zhang J.G., Basgen J., Li Z., et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26 (2006) 430-436
105. Little W.C., Zile M.R., Kitzman D.W., Hundley W.G., O'Brien T.X., and Degroof R.C. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 (2005) 191-195
106. Vasan S., Foiles P., and Founds H. Therapeutic potential of breakers of advanced glycation end-product-protein crosslinks. Arch Biochem Biophys 419 (2003) 89-96
107. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A., deGroof R.C., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
108. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66 (2004) 2137-2147
109. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end-products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16 (2005) 2363-2372
110. Davis B.J., Forbes J.M., Thomas M.C., Jerums G., Burns W.C., Kawachi H., et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47 (2004) 89-97
111. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end-products: biochemical mechanisms. J Am Soc Nephrol 13 (2002) 2478-2487
112. Cuccurullo C., Iezzi A., Fazia M.L., De Cesare D., Di Francesco A., Muraro R., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 (2006) 2716-2723
113. Ruggiero-Lopez D., Lecomte M., Moinet G., Patereau G., Lagarde M., and Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end-product formation. Biochem Pharmacol 58 (1999) 1765-1773
114. Scheen A.J., Paquot N., and Lefebvre P.J. United Kingdom Prospective Diabetes Study (UKPDS): 10 years later. Rev Med Liege 63 (2008) 624-629
115. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., and Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301 (2000) 65-77
116. Bonnefont-Rousselot D. Antioxidant and anti-AGE therapeutics: evaluation and perspectives. J Soc Biol 195 (2001) 391-398
117. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran Jr. L.J., et al. Receptor for advanced glycation end-products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21 (2001) 905-910
118. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
119. Flyvbjerg A., Denner L., Schrijvers B.F., Tilton R.G., Mogensen T.H., Paludan S.R., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53 (2004) 166-172
120. Jensen L.J., Denner L., Schrijvers B.F., Tilton R.G., Rasch R., and Flyvbjerg A. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol 188 (2006) 493-501